Trials / Terminated
TerminatedNCT00496158
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
A Multi-Center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared With Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naïve Patients With HBeAg Negative Chronic Hepatitis Due to Hepatitis B Virus
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Pharmasset · Industry
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
The objectives of this study are to compare in nucleoside treatment-naïve subjects, the efficacy and safety of clevudine 30 mg once daily versus adefovir 10 mg once daily, each as monotherapy, for 48 weeks, 72 weeks, and 96 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Clevudine | |
| DRUG | Adefovir |
Timeline
- Start date
- 2007-08-01
- First posted
- 2007-07-04
- Last updated
- 2009-04-27
Locations
119 sites across 11 countries: United States, Argentina, Australia, Canada, China, Greece, Puerto Rico, Spain, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00496158. Inclusion in this directory is not an endorsement.